Precipio, Inc. reported preliminary, unaudited results for the fourth quarter and full fiscal year 2025, showing total revenue of $24.0 million—an increase of 30 % from $18.5 million in 2024. Q4 revenue rose to $6.7 million, up 23 % from $5.4 million in Q4 2024, and the company’s overall revenue growth was driven by continued demand for its pathology services and proprietary diagnostic products.
The company’s two main revenue streams—Pathology Services and Product Sales—contributed to the growth. In Q3 2025, Pathology Services generated $6.0 million and Product Sales $0.72 million, while Q4 revenue of $6.7 million reflects a similar mix, underscoring the sustained adoption of both services and products. Compared with Q3 2025’s $6.8 million, Q4 revenue was slightly lower, indicating a modest slowdown in the quarter‑to‑quarter cycle but still a strong year‑over‑year performance.
Precipio’s profitability metrics improved markedly. Adjusted EBITDA reached $0.95 million in Q4 2025 and $1.23 million for the full year, a turnaround from a $1.5 million loss in FY 2024. Operating cash flow also turned positive, signaling the company’s shift from a cash‑burning growth model to a cash‑generating, self‑sustaining operation. The margin expansion—from a 27 % gross margin in Q1 2024 to 44 % in Q3 2025—further illustrates the company’s ability to scale and control costs.
CEO Ilan Danieli said, "2025 was a great year for us, one where the business performed well, and shareholders saw their value triple. We are confident in our ability to continue to create this value." He added, "Becoming an EBITDA and cash‑flow positive business has a very important impact on how we manage the business. It allows us to now invest in growth projects that consider a longer‑term perspective for the Company, rather than a constant focus on short‑term cash burn considerations."
The results position Precipio to fund future expansion without additional dilutive financing. With a growing customer base, improving margins, and a positive cash flow profile, the company is better equipped to pursue new product launches and market penetration, reinforcing its trajectory toward sustained profitability and shareholder value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.